BRIEF: Amgen is expecting growth over 5 years
TMCnet - The World's Largest Communications and Technology Community
TMC Launches New Sites ::  NGC  |  4GWE  |  Green Tech  |  Satellite  |  IT |  ITEXPO  |  Healthcare  |  Smart Grid  |  M2M  |  Smart Products  |  AstriCon News  |  SATCON News
Share
TMCnews
[November 08, 2008]

BRIEF: Amgen is expecting growth over 5 years

(Ventura County Star (CA) Via Acquire Media NewsEdge) Nov. 8--NEW YORK -- Amgen Inc. is expecting strong growth in the coming years, saying it could see two of its drugs reach blockbuster status in the next five years.

The Thousand Oaks-based company held a business review meeting with about 200 analysts and investors on Friday in New York. Chief Executive Kevin Sharer said Amgen now has five blockbuster drugs on the market, drugs that exceed $1 billion in annual sales. In the coming years, he said the company's drug Sensipar could pass that milestone.



Also, a yet-to-be-approved drug that keeps the body from breaking down bone, denosumab, could also reach blockbuster sales in treating osteoporosis and cancer- related treatment, he said.

The company's top selling drug, Aranesp, has been hard-hit by concerns about anemia drug safety. Amgen expects another 10 to 20 percent decline in Aranesp sales before it stabilizes.



The company's stock rose $2.31 to $58.87 Friday.

To see more of the Ventura County Star, or to subscribe to the newspaper, go to http://www.venturacountystar.com.

Copyright (c) 2008, Ventura County Star, Calif.
Distributed by McClatchy-Tribune Information Services.
For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

[ Back To TMCnet.com's Homepage ]


Discussions:
Be the first to post a comment on this page!
 
By  
TMCnet
TMCnet Videos
Featured White Papers
Top Stories
Related VoIP News

Subscribe FREE to all of TMC's monthly magazines. Click here now.